SCHEMBL10256642

SCHEMBL10256642

CN(CC[N+](C)(C)Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.55
PRMT6 Q96LA8 1/20 0.55
PRMT8 Q9NR22 1/20 0.55
DNM1 Q05193 2/20 0.50
SIGMAR1 Q99720 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TP53 P04637 1/20 0.49
MAPK1 P28482 1/20 0.49
TSHR P16473 3/20 0.47
HTT P42858 2/20 0.47
ALDH1A1 P00352 4/20 0.45
MAOB P27338 4/20 0.44
LMNA P02545 2/20 0.44
MAOA P21397 2/20 0.44
USP2 O75604 1/20 0.44
CYP3A4 P08684 1/20 0.44
PYCR1 P32322 1/20 0.44
KDM4E B2RXH2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13762993 0.87 SIGMAR1 (0.61) CARM1PRMT6PRMT8DNM1SIGMAR1
SCHEMBL17430873 0.86 DNM1 (0.54) CARM1PRMT6PRMT8DNM1SIGMAR1
SCHEMBL5051511 0.84 ACHE (0.56) SIGMAR1SMN1; SMN2
SCHEMBL30140977 0.83 DNM1 (0.55) DNM1SIGMAR1SMN1; SMN2MEN1KMT2A
Bromide SCHEMBL4775467 0.82 ACHE (0.53) SIGMAR1SMN1; SMN2
SCHEMBL5963139 0.78 DNM1 (0.67) DNM1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL7055109 0.78 CARM1 (0.75) CARM1PRMT6PRMT8SIGMAR1SMN1; SMN2
SCHEMBL10256762 0.76 DNM1 (0.61) DNM1SIGMAR1SMN1; SMN2MEN1KMT2A
Bromide SCHEMBL2355283 0.76 DNM1 (0.68) DNM1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL15790868 0.76 DNM1 (0.60) DNM1SIGMAR1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170059992-A1 RESIST PATTERN-FORMING METHOD AND CHEMICALLY AMPLIFIED RADIATION-SENSITIVE RESIN COMPOSITION JSR CORPORATION (JP) 2017-03-02 US disclosed
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2012-01-19 US disclosed
EP-1535913-B1 NOVEL QUATERNARY AMMONIUM COMPOUNDS ASAHI KASEI PHARMA CORP (JP) 2011-11-02 EP disclosed
US-7973030-B2 Benzothiazepine and benzothiepine compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-07-05 US disclosed
US-7803792-B2 Quaternary ammonium compounds ASAHI KASEI PHARMA CORPORATION (JP) 2010-09-28 US disclosed
US-7312208-B2 Quaternary ammonium compounds ASAHI KASEI PHARMA CORPORATION (JP) 2007-12-25 US disclosed
US-20070203115-A1 Novel quaternary ammonium compounds ASAHI KASEI PHARMA CORPORATION (JP) 2007-08-30 US disclosed
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds ASHAI KASEI PHARAMA CORPORATION (JP) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203115-A1 Novel quaternary ammonium compounds SLC10A2, SLC10A1, ABCB11 CARM1 3896/4885PRMT6 1040/4885PRMT8 2074/4885
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS SLC10A1, SREBF1, SPTLC1 CARM1 1118/4885PRMT6 2215/4885PRMT8 986/4885
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds SLC10A1, GOT1, CES1 CARM1 1726/4885PRMT6 2375/4885PRMT8 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.